phosphatidylinositol 4 kinases

PIK-93, the first potent synthetic PI4K inhibitor, exhibits an IC50 of 19 nM and also inhibits PI3Kα with an IC50 of 39 nM.

GSK-A1 is a specific inhibitor of PI4KA, also inhibited calcium-driven PRL secretion without affecting calcium signaling and Prl expression. GSK-A1 has anti-hepatitis C virus (HCV) potential.

BF738735 is a selective inhibitor of phosphatidylinositol 4-kinase III beta (PI4KIIIβ, IC50 = 5.7 nM) showing higher activity over α(IC50 = 1.7 μM). BF738735 exhibits a broad spectrum of antiviral activity.

ARUK2001607 is a selective inhibitor of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ, Kd= 7.1 nM). ARUK2001607 exhibits high selectivity over other >150 kinases.

UCB9608 is a selective and orally active PI4KIIIβ inhibitor (IC50: 11 nM), selective over PI3KC2 α, β, and γ lipid kinases.

PI4KIIIbeta-IN-9 is a potent inhibitor of PI4KIIIβ [IC50 of 7 nM].

MMV390048 is an antimalarial agent and is a representative of a new chemical class of Plasmodium PI4K inhibitor (Kdapp=0.3 μM). MMV390048 binds to the ATP binding site of Plasmodium PI4K and does not bind to other P. falciparum and human kinases apart from human PIP4K2C, thus alleviating potential kinase-mediated safety concerns.

BQR-695 (NVP-BQR695) is a phosphatidylinositol 4-kinase (PI4K) inhibitor with IC50s of 80 and 3.5 nM for human PI4KIIIβ and Plasmodium variant of PI4KIIIβ, respectively.

PI4KIIIbeta-IN-10 is a potent inhibitor of PI4KIIIβ with an IC50 value of 3.6 nM.

GSK-F1 (PI4KA inhibitor-F1) is a novel potent PI4KA inhibitor.

KDU691 is a PI4K inhibitor.

T-00127_HEV1 is an inhibitor of phosphatidylinositol 4-kinase III beta (IC50: 60 nM).

PI-273, a Substrate-Competitive, Specific Small-Molecule Inhibitor of PI4KIIα, Inhibits the Growth of Breast Cancer Cells